{
    "clinical_study": {
        "@rank": "25011", 
        "acronym": "MUC", 
        "arm_group": [
            {
                "arm_group_label": "VB-201 160mg", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will received 80mg twice daily for 24 weeks."
            }, 
            {
                "arm_group_label": "Placebo with crossover to VB-201 160mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects on placebo will crossover to VB-201 160 at week 12."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine the safety and efficacy in subjects with mild to moderate ulcerative\n      colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and\n      other assessments."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, \u226518 years of age, who has a diagnosis of active UC for at least 6\n             months prior to screening\n\n          -  A rectal/colonic biopsy obtained previously and consistent with a diagnosis of UC\n\n          -  Endoscopy (flexible sigmoidoscopy unless surveillance colonoscopy is clinically\n             indicated) confirming diagnosis of UC within 2 weeks prior to randomization\n\n          -  Endoscopy (flexible sigmoidoscopy unless surveillance colonoscopy is clinically\n             indicated) confirming diagnosis of UC within 2 weeks prior to randomization\n\n          -  Active UC despite previous treatment with at least one 5-ASA compound at a dose of\n             \u22652000 mg/day for at least 4 weeks or documented intolerance to such therapy\n\n        Exclusion Criteria:\n\n          -  Diagnosis of indeterminate colitis, Crohn's disease, or clinical findings suggestive\n             of Crohn's disease (fistula or granulomas on biopsy) or microscopic colitis\n             (collagenous colitis or lymphocytic colitis)\n\n          -  Subject whose symptoms are likely caused by factors other than inflammatory UC,\n             including infection or irritable bowel syndrome (IBS)\n\n          -  History of dysplasia on colonic biopsy\n\n          -  Subject with \u2265 8 year history of pancolitis or \u2265 15 year history of left sided\n             colitis unless a colonoscopy with surveillance biopsies to screen for colon cancer\n             has been performed within the past year\n\n          -  Subject \u2265 50 years of age who has not had a colonoscopy to screen for colorectal\n             polyps and colon cancer within the past 5 years\n\n          -  Subject who has had any prior surgical resection of any part of the colon excluding\n             the appendix\n\n          -  Previous treatment with any biologic product including investigational biologic\n             products\n\n          -  The subject is taking Systemic corticosteroids,\n             Azathioprine/6-mercaptopurine/methotrexate, immunosuppressants, Oral 5-ASA compounds\n             unless they have been on a stable dose of sufficient duration prior to Baseline. If\n             recently discontinued the subject must have had a wash-out periods of sufficient\n             duration prior to Baseline\n\n          -  Rectally administered corticosteroids or 5-ASA, antibiotics for the treatment of UC\n             and probiotics within 14 days of the Baseline Visit and throughout the study\n\n          -  The subject has with a stool culture positive for pathogenic ova or parasites,\n             enteric pathogens or Clostridium difficile toxin at the Screening Visit\n\n          -  Presence of, or history of cancer, with the exception of skin cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839214", 
            "org_study_id": "VB-201-064"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VB-201 160mg", 
                    "Placebo with crossover to VB-201 160mg"
                ], 
                "intervention_name": "VB-201 160mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo with crossover to VB-201 160mg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Warsaw", 
                    "country": "Poland"
                }, 
                "name": "VBL Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis", 
        "other_outcome": [
            {
                "description": "As measured by changes from baseline in physical exam, vital signs, ECG, concomitant medications, laboratory values.", 
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline through safety follow up at Week 28"
            }, 
            {
                "description": "The proportion of subjects in each arm with a 2-point or greater decrease in the Modified Mayo score at Weeks 12 and 24.", 
                "measure": "Reduction in Modified Mayo Score", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and Week 24"
            }, 
            {
                "description": "Change in the modified Baron score from Baseline to Weeks 12 and 24 in the VB-201 treatment group as compared to the placebo group.", 
                "measure": "Modified Baron Score", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and Week 24"
            }, 
            {
                "description": "The proportion of subjects in each arm with mucosal healing at Weeks 12 and 24 in the VB-201 treatment group compared to placebo group.", 
                "measure": "Mucosal Healing", 
                "safety_issue": "No", 
                "time_frame": "Wee 12 and Week 24"
            }
        ], 
        "overall_contact": {
            "email": "yaelc@vblrx.com", 
            "last_name": "Yael Cohen, MD", 
            "phone": "+972-3-634-6450"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Bulgaria: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of subjects in remission at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.", 
            "measure": "Modified Mayo Score indicating remission", 
            "safety_issue": "No", 
            "time_frame": "Week 12 and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The proportion of subjects responding at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.", 
            "measure": "Modified Mayo Score indicating response", 
            "safety_issue": "No", 
            "time_frame": "Week 12 and Week 24"
        }, 
        "source": "Vascular Biogenics Ltd. operating as VBL Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vascular Biogenics Ltd. operating as VBL Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}